| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| João Carlos Locatelli, Juliene Gonçalves Costa, Andrew Haynes, Louise H Naylor, P Gerry Fegan, Bu B Yeap, Daniel J Gree. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes care. 2024-04-30. PMID:38687506. |
liraglutide and semaglutide (glp-1ra), tirzepatide (glp-1 and gip receptor dual agonist), and retatrutide (glp-1, gip, and glucagon receptor triple agonist) are peptides with incretin agonist activity that induce ∼15-24% weight loss in adults with overweight and obesity, alongside beneficial impacts on blood pressure, cholesterol, blood glucose, and insulin. |
2024-04-30 |
2024-05-03 |
Not clear |
| Jo E Lewis, Danae Nuzzaci, Paula-Peace James-Okoro, Mireia Montaner, Elisabeth O'Flaherty Rottenberger, Tamana Darwish, Marito Hayashi, Stephen D Liberles, David Hornigold, Jacqueline Naylor, David Baker, Fiona M Gribble, Frank Reiman. Stimulating intestinal GIP release reduces food intake and body weight in mice. Molecular metabolism. 2024-04-23. PMID:38653401. |
glucose dependent insulinotropic polypeptide (gip) is well established as an incretin hormone, boosting glucose-dependent insulin secretion. |
2024-04-23 |
2024-04-26 |
mouse |
| Giulia Angelini, Sara Russo, Geltrude Mingron. Incretin hormones, obesity and gut microbiota. Peptides. 2024-04-18. PMID:38636809. |
gip (glucose-dependent insulinotropic polypeptide) and glp-1 (glucagon-like peptide-1), which are secreted from the intestine after nutrient intake and stimulate insulin secretion from pancreatic β cells, influence lipid metabolism, gastric empting, appetite and body weight. |
2024-04-18 |
2024-04-21 |
Not clear |
| Anne-Sofie H Jensen, Henriette Ytting, Mikkel P Werge, Elias B Rashu, Liv E Hetland, Mira Thing, Puria Nabilou, Johan Burisch, Kirstine N Bojsen-Møller, Anders E Junker, Lise Hobolth, Christian Mortensen, Flemming Tofteng, Flemming Bendtsen, Søren Møller, Mogens Vyberg, Reza R Serizawa, Lise L Gluud, Nicolai J Wewer Albrechtse. Patients with autoimmune liver disease have glucose disturbances that mechanistically differ from steatotic liver disease. American journal of physiology. Gastrointestinal and liver physiology. 2024-04-16. PMID:38625142. |
we measured the concentrations of glucose, c-peptide, insulin, glucagon, the two incretin hormones glucose insulinotropic peptide (gip) and glucagon-like peptide-1 (glp-1). |
2024-04-16 |
2024-04-18 |
Not clear |
| Lampros G Chrysavgis, Spyridon Kazanas, Konstantina Bafa, Sophia Rozani, Maria-Evangelia Koloutsou, Evangelos Cholongita. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature. International journal of molecular sciences. vol 25. issue 7. 2024-04-13. PMID:38612640. |
glucagon-like peptide 1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are incretins that regulate postprandial glucose regulation, stimulating insulin secretion from pancreatic β-cells in response to food ingestion. |
2024-04-13 |
2024-04-15 |
human |
| Samrin Kagdi, Sulayman Lyons, Jacqueline L Beaudr. The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue. The Journal of endocrinology. 2024-04-05. PMID:38579777. |
glucose-dependent insulinotropic polypeptide (gip) is an incretin hormone secreted from the small intestinal k-cells, responsible for augmenting insulin release, and has gained attention for its independent and amicable effects with glucagon-like peptide-1 (glp-1), another incretin hormone secreted from the small intestinal l-cells. |
2024-04-05 |
2024-04-10 |
human |
| Samrin Kagdi, Sulayman Lyons, Jacqueline L Beaudr. The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue. The Journal of endocrinology. 2024-04-05. PMID:38579777. |
the gip receptor (gipr) is found in whole adipose tissue, whereas the glp-1 receptor (glp-1r) is not, and some studies suggest that gipr action lowers body weight and plays a role in lipolysis, glucose/lipid uptake/disposal, adipose tissue blood flow, lipid oxidation, and free-fatty acid (ffa) re-esterification that may or may not be influenced by other hormones such as insulin. |
2024-04-05 |
2024-04-10 |
human |
| Kayoko Kamemoto, Yusei Tataka, Ayano Hiratsu, Chihiro Nagayama, Yuka Hamada, Koji Kurata, Michiko Chiyoda, Machi Ito, Masashi Miyashit. Effect of vegetable consumption with chewing on postprandial glucose metabolism in healthy young men: a randomised controlled study. Scientific reports. vol 14. issue 1. 2024-03-30. PMID:38555375. |
circulating concentrations of glucose, insulin, total glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic peptide (gip) concentrations were measured from the plasma. |
2024-03-30 |
2024-04-02 |
Not clear |
| Kayoko Kamemoto, Yusei Tataka, Ayano Hiratsu, Chihiro Nagayama, Yuka Hamada, Koji Kurata, Michiko Chiyoda, Machi Ito, Masashi Miyashit. Effect of vegetable consumption with chewing on postprandial glucose metabolism in healthy young men: a randomised controlled study. Scientific reports. vol 14. issue 1. 2024-03-30. PMID:38555375. |
although plasma glucose concentrations did not differ between the trials, the plasma insulin and gip incremental area under the curve values were higher in the chewing than in the non-chewing trial. |
2024-03-30 |
2024-04-02 |
Not clear |
| Christopher Bannon, Claire Meek, Frank Reimann, Fiona M Gribbl. Fasting and Post Prandial Pancreatic and Enteroendocrine Hormone Levels in Obese and Non-Obese Participants. Peptides. 2024-03-15. PMID:38490484. |
participants: with healthy bmi (n=15), overweight bmi (n=29) and obesity (n=161) had samples taken fasting and 30min post mixed liquid meal for analysis of glucagon-like peptide-1 (glp-1), pyy, glucose-dependent insulinotropic polypeptide (gip), insulin and glucagon. |
2024-03-15 |
2024-03-18 |
human |
| Christopher Bannon, Claire Meek, Frank Reimann, Fiona M Gribbl. Fasting and Post Prandial Pancreatic and Enteroendocrine Hormone Levels in Obese and Non-Obese Participants. Peptides. 2024-03-15. PMID:38490484. |
data visualiation used linear discriminant analysis for dimensionality reduction, to visualise the data and assess scaling of each hormone fasting levels of insulin, gip and pyy were shown to be key classifiers between the 3 groups on ancova analysis, with an observation of increased gip levels in overweight, but not obese participants. |
2024-03-15 |
2024-03-18 |
human |
| Christopher Bannon, Claire Meek, Frank Reimann, Fiona M Gribbl. Fasting and Post Prandial Pancreatic and Enteroendocrine Hormone Levels in Obese and Non-Obese Participants. Peptides. 2024-03-15. PMID:38490484. |
in non-obese subjects, fasting gip, pyy and insulin correlated with bmi, whereas in obese people only the pancreatic hormones glucagon and insulin correlated with bmi. |
2024-03-15 |
2024-03-18 |
human |
| Dorte B Zilstorff, Michael M Richter, Jens Hannibal, Henrik L Jørgensen, Henriette P Sennels, Nicolai J Wewer Albrechtse. Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males. BMC endocrine disorders. vol 24. issue 1. 2024-03-14. PMID:38481208. |
glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are secreted from gut endocrine cells during meals and control glucose homeostasis by potentiating insulin secretion and inhibiting food intake. |
2024-03-14 |
2024-03-16 |
Not clear |
| Angyi Lin, Hideki Kitaura, Fumitoshi Ohori, Takahiro Noguchi, Aseel Marahleh, Jinghan Ma, Jiayi Ren, Mariko Miura, Ziqiu Fan, Kohei Narita, Itaru Mizoguch. (D-Ala International journal of molecular sciences. vol 25. issue 5. 2024-03-13. PMID:38473802. |
(d-ala glucose-insulinotropic polypeptide (gip) is an incretin hormone that induces insulin secretion and decreases blood glucose levels. |
2024-03-13 |
2024-03-15 |
Not clear |
| Kathleen M Sicinski, Damla Sürmeli, Jasper Du, Venkata S Raman, Vittorio Montanari, Minhee Lee, Benjamin N Harwood, Alan S Kopin, Martin Beinborn, Krishna Kuma. A Robust Platform for the Molecular Design of Potent, Protease-Stable, Long-Acting GIP Analogues. Journal of medicinal chemistry. 2024-03-08. PMID:38458970. |
gip binds to its cognate receptor, gipr, and mediates metabolic physiology by improved insulin sensitivity, β-cell proliferation, increased energy consumption, and stimulated glucagon secretion. |
2024-03-08 |
2024-03-11 |
Not clear |
| Samuel Mendoza-Pérez, Itzel Orta-Méndez-Y-Sánchez, Rolando Salvador García-Gómez, Guillermo Ordaz-Nava, María Isabel Gracia-Mora, Lucía Macías-Rosales, Héctor A Rico-Morales, Gerardo Salas-Garrido, María Del Carmen Durán-Domínguez-de-Bazú. Stevia rebaudiana Bertoni, an American plant used as sweetener: Study of its effects on body mass control and glycemia reduction in Wistar male and female rats. PloS one. vol 19. issue 2. 2024-02-27. PMID:38412182. |
euthanasia was done and blood serum was collected to evaluate the following biochemical parameters: glucose, triglycerides, cholesterol, insulin, glucagon, leptin, ghrelin, and glucose-dependent insulinotropic peptide, gip. |
2024-02-27 |
2024-03-01 |
rat |
| Xin Jiang, Ji Li, Xiaohui Yao, Hao Ding, Aihong Gu, Zhen Zho. Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer's disease: a narrative review. Frontiers in pharmacology. vol 15. 2024-02-26. PMID:38405664. |
beyond dpp4i's benefits in alleviating insulin resistance and glucose-lowering, underlying mechanisms for the potential neuroprotection with dpp4i medications were categorized into the following sections: (ferrari et al., physiol rev, 2021, 101, 1,047-1,081): the benefits of dpp4is on directly ameliorating the burden of β-amyloid plaques and reducing the formation of neurofibrillary tangles; dpp4i increasing the bioactivity of neuroprotective dpp4 substrates including glucagon-like peptide-1 (glp-1), glucose-dependent insulinotropic peptide (gip), and stromal-derived factor-1α (sdf-1α) etc. |
2024-02-26 |
2024-02-28 |
Not clear |
| Rolien Bosch, Marcella Petrone, Rosalin Arends, Paolo Vicini, Eric J G Sijbrands, Sven Hoefman, Nelleke Snelde. Characterisation of cotadutide's dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model. British journal of pharmacology. 2024-02-25. PMID:38403793. |
we characterised the effects of cotadutide on glucose, insulin, glp-1, gip, and glucagon over time in a quantitative manner using our glucose dynamics systems model (4gi systems model), in combination with clinical data from a multiple ascending dose/phase 2a (mad/ph2a) study in overweight and obese subjects with a history of type 2 diabetes mellitus (nct02548585). |
2024-02-25 |
2024-02-28 |
human |
| Snehasish Nag, Samanwita Mandal, Oindrila Mukherjee, Tanmay Majumdar, Satinath Mukhopadhyay, Rakesh Kund. Vildagliptin inhibits high fat and fetuin-A mediated DPP-4 expression, intracellular lipid accumulation and improves insulin secretory defects in pancreatic beta cells. Biochimica et biophysica acta. Molecular basis of disease. vol 1870. issue 3. 2024-02-03. PMID:38296116. |
dipeptidyl peptidase-4 (dpp-4), a ubiquitous proteolytic enzyme, inhibits insulin secretion from pancreatic beta cells by inactivating circulating incretin hormones glp-1 and gip. |
2024-02-03 |
2024-02-06 |
mouse |
| Marta Santos Hernandez, Frank Reimann, Fiona M Gribbl. Cellular mechanisms of incretin hormone secretion. Journal of molecular endocrinology. 2024-01-19. PMID:38240302. |
the incretin hormones glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are involved in the regulation of insulin secretion, appetite, food intake and body weight after their nutrient-induced secretion from the gut. |
2024-01-19 |
2024-01-21 |
Not clear |